Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia.
Jumpei TemmokuMasayuki MiyataEiji SuzukiYuya SumichikaKenji SaitoShuhei YoshidaHaruki MatsumotoYuya FujitaNaoki MatsuokaTomoyuki AsanoShuzo SatoHiroshi WatanabeKiyoshi MigitaPublished in: Journal of clinical medicine (2023)
These findings suggest that lymphopenia during the first 4 months from the initiation of JAKi is associated with reduced drug retention rates in patients with RA due to AEs, which is exclusively associated with the use of tofacitinib.